Table 3.
Model results (lifetime means per patient)
| Surgical | Conventional | Difference | |
|---|---|---|---|
| Undiscounted | |||
| Years in diabetes remission | 11.4 | 2.1 | 9.4 |
| Total life-years | 32.1 | 30.5 | 1.6 |
| QALYs | 24.9 | 22.6 | 2.3 |
| Discounted at 3% for both costs and benefits | |||
| Costs (AUD) | |||
| 2-year RCT intervention | 13,383 | 3,397 | 9,987 |
| Surgical intervention maintenance | 6,477 | 6,477 | |
| Surgical intervention complications | 1,768 | 1,768 | |
| Type 2 diabetes remission—monitoring costs | 16,479 | 2,874 | 13,605 |
| Health care costs to treat type 2 diabetes | 60,824 | 95,105 | (34,281) |
| Total cost | 98,931 | 101,376 | (2,444) |
| Effectiveness | |||
| Total life-years | 20.0 | 19.2 | 0.7 |
| QALYs | 15.7 | 14.5 | 1.2 |
| Cost-effectiveness | |||
| Cost per life-year gained | Dominant | ||
| Cost per QALY | Dominant | ||
| Probability of dominance | 57% | ||
| Probability of cost-effectiveness at willingness-to-pay threshold | 98% |
Dominant: generates health care savings and health benefits. Willingness–to–pay threshold, 50,000 AUD per QALY.